These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34504197)

  • 1. RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines.
    Stubbs CK; Biancucci M; Vidimar V; Satchell KJF
    Sci Rep; 2021 Sep; 11(1):17925. PubMed ID: 34504197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling.
    Biancucci M; Minasov G; Banerjee A; Herrera A; Woida PJ; Kieffer MB; Bindu L; Abreu-Blanco M; Anderson WF; Gaponenko V; Stephen AG; Holderfield M; Satchell KJF
    Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of inactivation of Ras and Rap1 small GTPases by Ras/Rap1-specific endopeptidase from the sepsis-causing pathogen
    Jang SY; Hwang J; Kim BS; Lee EY; Oh BH; Kim MH
    J Biol Chem; 2018 Nov; 293(47):18110-18122. PubMed ID: 30282804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts.
    Vidimar V; Park M; Stubbs CK; Ingram NK; Qiang W; Zhang S; Gursel D; Melnyk RA; Satchell KJF
    Mol Cancer Ther; 2022 May; 21(5):810-820. PubMed ID: 35247912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate Recognition of MARTX Ras/Rap1-Specific Endopeptidase.
    Biancucci M; Rabideau AE; Lu Z; Loftis AR; Pentelute BL; Satchell KJF
    Biochemistry; 2017 May; 56(21):2747-2757. PubMed ID: 28459538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2021 Nov; 17(12):104. PubMed ID: 34822010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
    Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
    Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
    Sheffels E; Sealover NE; Theard PL; Kortum RL
    Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery.
    Escher TE; Yuk SA; Qian Y; Stubbs CK; Scott EA; Satchell KJF
    bioRxiv; 2024 Jun; ():. PubMed ID: 38948803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
    Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
    Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth.
    Vidimar V; Beilhartz GL; Park M; Biancucci M; Kieffer MB; Gius DR; Melnyk RA; Satchell KJF
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):16938-16948. PubMed ID: 32616570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
    Lee CS; Lee LC; Yuan TL; Chakka S; Fellmann C; Lowe SW; Caplen NJ; McCormick F; Luo J
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4508-4517. PubMed ID: 30709910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenomedullin is a therapeutic target in colorectal cancer.
    Wang L; Gala M; Yamamoto M; Pino MS; Kikuchi H; Shue DS; Shirasawa S; Austin TR; Lynch MP; Rueda BR; Zukerberg LR; Chung DC
    Int J Cancer; 2014 May; 134(9):2041-50. PubMed ID: 24519534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
    Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute Quantification of Endogenous Ras Isoform Abundance.
    Mageean CJ; Griffiths JR; Smith DL; Clague MJ; Prior IA
    PLoS One; 2015; 10(11):e0142674. PubMed ID: 26560143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.